Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review

Feifei Teng; Xiangjiao Meng; Li Kong; Jinming Yu

doi:10.1016/j.canlet.2017.11.014

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients

Ott, P.A.; Hodi, F.S.; Robert, C.

Therapeutic antibodies against intracellular tumor antigens

Trenevska, I.; Li, D.; Banham, A.H.

The blockade of immune checkpoints in cancer immunotherapy, Nature reviews

Pardoll, D.M.

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Robert, C.; Thomas, L.; Bondarenko, I.; O'Day, S.; Weber, J.; Garbe, C.; Lebbe, C.; Baurain, J.F.; Testori, A.; Grob, J.J.; Davidson, N.; Richards, J.; Maio, M.; Hauschild, A.; Miller, W.H.; Gascon, P.; Lotem, M.; Harmankaya, K.; Ibrahim, R.; Francis, S.; Chen, T.T.; Humphrey, R.; Hoos, A.; Wolchok, J.D.

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Holgado, E.; Barlesi, F.; Kohlhaufl, M.; Arrieta, O.; Burgio, M.A.; Fayette, J.; Lena, H.; Poddubskaya, E.; Gerber, D.E.; Gettinger, S.N.; Rudin, C.M.; Rizvi, N.; Crino, L.; Blumenschein, G.R.; Antonia, S.J.; Dorange, C.; Harbison, C.T.; Graf Finckenstein, F.; Brahmer, J.R.

Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

Brahmer, J.; Reckamp, K.L.; Baas, P.; Crino, L.; Eberhardt, W.E.; Poddubskaya, E.; Antonia, S.; Pluzanski, A.; Vokes, E.E.; Holgado, E.; Waterhouse, D.; Ready, N.; Gainor, J.; Aren Frontera, O.; Havel, L.; Steins, M.; Garassino, M.C.; Aerts, J.G.; Domine, M.; Paz-Ares, L.; Reck, M.; Baudelet, C.; Harbison, C.T.; Lestini, B.; Spigel, D.R.

Pembrolizumab for the treatment of non-small-cell lung cancer

Garon, E.B.; Rizvi, N.A.; Hui, R.; Leighl, N.; Balmanoukian, A.S.; Eder, J.P.; Patnaik, A.; Aggarwal, C.; Gubens, M.; Horn, L.; Carcereny, E.; Ahn, M.J.; Felip, E.; Lee, J.S.; Hellmann, M.D.; Hamid, O.; Goldman, J.W.; Soria, J.C.; Dolled-Filhart, M.; Rutledge, R.Z.; Zhang, J.; Lunceford, J.K.; Rangwala, R.; Lubiniecki, G.M.; Roach, C.; Emancipator, K.; Gandhi, L.

Nivolumab in previously untreated melanoma without BRAF mutation

Robert, C.; Long, G.V.; Brady, B.; Dutriaux, C.; Maio, M.; Mortier, L.; Hassel, J.C.; Rutkowski, P.; McNeil, C.; Kalinka-Warzocha, E.; Savage, K.J.; Hernberg, M.M.; Lebbe, C.; Charles, J.; Mihalcioiu, C.; Chiarion-Sileni, V.; Mauch, C.; Cognetti, F.; Arance, A.; Schmidt, H.; Schadendorf, D.; Gogas, H.; Lundgren-Eriksson, L.; Horak, C.; Sharkey, B.; Waxman, I.M.; Atkinson, V.; Ascierto, P.A.

Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma

Schadendorf, D.; Hodi, F.S.; Robert, C.; Weber, J.S.; Margolin, K.; Hamid, O.; Patt, D.; Chen, T.T.; Berman, D.M.; Wolchok, J.D.

Combined nivolumab and ipilimumab or monotherapy in untreated melanoma

Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Schadendorf, D.; Dummer, R.; Smylie, M.; Rutkowski, P.; Ferrucci, P.F.; Hill, A.; Wagstaff, J.; Carlino, M.S.; Haanen, J.B.; Maio, M.; Marquez-Rodas, I.; McArthur, G.A.; Ascierto, P.A.; Long, G.V.; Callahan, M.K.; Postow, M.A.; Grossmann, K.; Sznol, M.; Dreno, B.; Bastholt, L.; Yang, A.; Rollin, L.M.; Horak, C.; Hodi, F.S.; Wolchok, J.D.

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

Brahmer, J.R.; Drake, C.G.; Wollner, I.; Powderly, J.D.; Picus, J.; Sharfman, W.H.; Stankevich, E.; Pons, A.; Salay, T.M.; McMiller, T.L.; Gilson, M.M.; Wang, C.; Selby, M.; Taube, J.M.; Anders, R.; Chen, L.; Korman, A.J.; Pardoll, D.M.; Lowy, I.; Topalian, S.L.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; Leming, P.D.; Spigel, D.R.; Antonia, S.J.; Horn, L.; Drake, C.G.; Pardoll, D.M.; Chen, L.; Sharfman, W.H.; Anders, R.A.; Taube, J.M.; McMiller, T.L.; Xu, H.; Korman, A.J.; Jure-Kunkel, M.; Agrawal, S.; McDonald, D.; Kollia, G.D.; Gupta, A.; Wigginton, J.M.; Sznol, M.

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; Pitot, H.C.; Hamid, O.; Bhatia, S.; Martins, R.; Eaton, K.; Chen, S.; Salay, T.M.; Alaparthy, S.; Grosso, J.F.; Korman, A.J.; Parker, S.M.; Agrawal, S.; Goldberg, S.M.; Pardoll, D.M.; Gupta, A.; Wigginton, J.M.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Herbst, R.S.; Soria, J.C.; Kowanetz, M.; Fine, G.D.; Hamid, O.; Gordon, M.S.; Sosman, J.A.; McDermott, D.F.; Powderly, J.D.; Gettinger, S.N.; Kohrt, H.E.; Horn, L.; Lawrence, D.P.; Rost, S.; Leabman, M.; Xiao, Y.; Mokatrin, A.; Koeppen, H.; Hegde, P.S.; Mellman, I.; Chen, D.S.; Hodi, F.S.

Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial

Motzer, R.J.; Rini, B.I.; McDermott, D.F.; Redman, B.G.; Kuzel, T.M.; Harrison, M.R.; Vaishampayan, U.N.; Drabkin, H.A.; George, S.; Logan, T.F.; Margolin, K.A.; Plimack, E.R.; Lambert, A.M.; Waxman, I.M.; Hammers, H.J.

Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody [abstract]

S, A.; Segal, N.H.; Brahmer, J.R.; Maio, M.; Blake-Haskins, A.; Li, X.; Vasselli, J.; Ibrahim, R.A.; Lutzky, J.; Khleif, S.

Phase 1b study of pembrolizumab (pembro; MK-3475) in patients (pts) with advanced gastric cancer [abstract]

Y, B.; Muro, K.; Shankaran, V.; Geva, R.; Catenacci, D.V.T.; Gupta, S.; Eder, J.P.; Berger, R.; Gonzalez, E.J.; Pulini, J.

Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer

Reck, M.; Rodriguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csoszi, T.; Fulop, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; O'Brien, M.; Rao, S.; Hotta, K.; Leiby, M.A.; Lubiniecki, G.M.; Shentu, Y.; Rangwala, R.; Brahmer, J.R.

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A.; Barlesi, F.; Waterkamp, D.; Park, K.; Ciardiello, F.; von Pawel, J.; Gadgeel, S.M.; Hida, T.; Kowalski, D.M.; Dols, M.C.; Cortinovis, D.L.; Leach, J.; Polikoff, J.; Barrios, C.; Kabbinavar, F.; Frontera, O.A.; De Marinis, F.; Turna, H.; Lee, J.S.; Ballinger, M.; Kowanetz, M.; He, P.; Chen, D.S.; Sandler, A.; Gandara, D.R.; Group, O.A.K.S.

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Powles, T.; Eder, J.P.; Fine, G.D.; Braiteh, F.S.; Loriot, Y.; Cruz, C.; Bellmunt, J.; Burris, H.A.; Petrylak, D.P.; Teng, S.L.; Shen, X.; Boyd, Z.; Hegde, P.S.; Chen, D.S.; Vogelzang, N.J.

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Rosenberg, J.E.; Hoffman-Censits, J.; Powles, T.; van der Heijden, M.S.; Balar, A.V.; Necchi, A.; Dawson, N.; O'Donnell, P.H.; Balmanoukian, A.; Loriot, Y.; Srinivas, S.; Retz, M.M.; Grivas, P.; Joseph, R.W.; Galsky, M.D.; Fleming, M.T.; Petrylak, D.P.; Perez-Gracia, J.L.; Burris, H.A.; Castellano, D.; Canil, C.; Bellmunt, J.; Bajorin, D.; Nickles, D.; Bourgon, R.; Frampton, G.M.; Cui, N.; Mariathasan, S.; Abidoye, O.; Fine, G.D.; Dreicer, R.

Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice

Lau, J.; Cheung, J.; Navarro, A.; Lianoglou, S.; Haley, B.; Totpal, K.; Sanders, L.; Koeppen, H.; Caplazi, P.; McBride, J.; Chiu, H.; Hong, R.; Grogan, J.; Javinal, V.; Yauch, R.; Irving, B.; Belvin, M.; Mellman, I.; Kim, J.M.; Schmidt, M.

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity

Juneja, V.R.; McGuire, K.A.; Manguso, R.T.; LaFleur, M.W.; Collins, N.; Haining, W.N.; Freeman, G.J.; Sharpe, A.H.

A phase Ia study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC)

T, P.; Petrylak, D.P.; Bellmunt, J.; Braiteh, F.S.; Loriot, Y.; Zambrano, C.C.

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

Taube, J.M.; Klein, A.; Brahmer, J.R.; Xu, H.; Pan, X.; Kim, J.H.; Chen, L.; Pardoll, D.M.; Topalian, S.L.; Anders, R.A.

PD-L1 expression and intratumoral heterogeneity across breast cancer subtypes and stages: an assessment of 245 primary and 40 metastatic tumors

Dill, E.A.; Gru, A.A.; Atkins, K.A.; Friedman, L.A.; Moore, M.E.; Bullock, T.N.; Cross, J.V.; Dillon, P.M.; Mills, A.M.

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

Madore, J.; Vilain, R.E.; Menzies, A.M.; Kakavand, H.; Wilmott, J.S.; Hyman, J.; Yearley, J.H.; Kefford, R.F.; Thompson, J.F.; Long, G.V.; Hersey, P.; Scolyer, R.A.

Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer

McLaughlin, J.; Han, G.; Schalper, K.A.; Carvajal-Hausdorf, D.; Pelekanou, V.; Rehman, J.; Velcheti, V.; Herbst, R.; LoRusso, P.; Rimm, D.L.

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

Ilie, M.; Long-Mira, E.; Bence, C.; Butori, C.; Lassalle, S.; Bouhlel, L.; Fazzalari, L.; Zahaf, K.; Lalvee, S.; Washetine, K.; Mouroux, J.; Venissac, N.; Poudenx, M.; Otto, J.; Sabourin, J.C.; Marquette, C.H.; Hofman, V.; Hofman, P.

Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy

Adams, D.L.; Adams, D.K.; He, J.; Kalhor, N.; Zhang, M.; Xu, T.; Gao, H.; Reuben, J.M.; Qiao, Y.; Komaki, R.; Liao, Z.; Edelman, M.J.; Tang, C.M.; Lin, S.H.

Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma

Vilain, R.E.; Menzies, A.M.; Wilmott, J.S.; Kakavand, H.; Madore, J.; Guminski, A.; Liniker, E.; Kong, B.Y.; Cooper, A.J.; Howle, J.R.; Saw, R.P.M.; Jakrot, V.; Lo, S.; Thompson, J.F.; Carlino, M.S.; Kefford, R.F.; Long, G.V.; Scolyer, R.A.

PD-L1 testing in cancer: challenges in companion diagnostic development

Hansen, A.R.; Siu, L.L.

Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review

Sacher, A.G.; Gandhi, L.

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

Nishino, M.; Ramaiya, N.H.; Hatabu, H.; Hodi, F.S.

PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells

Mahoney, K.M.; Sun, H.; Liao, X.; Hua, P.; Callea, M.; Greenfield, E.A.; Hodi, F.S.; Sharpe, A.H.; Signoretti, S.; Rodig, S.J.; Freeman, G.J.

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

Weber, J.S.; Kudchadkar, R.R.; Yu, B.; Gallenstein, D.; Horak, C.E.; Inzunza, H.D.; Zhao, X.; Martinez, A.J.; Wang, W.; Gibney, G.; Kroeger, J.; Eysmans, C.; Sarnaik, A.A.; Chen, Y.A.

Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study

Thomas, N.E.; Busam, K.J.; From, L.; Kricker, A.; Armstrong, B.K.; Anton-Culver, H.; Gruber, S.B.; Gallagher, R.P.; Zanetti, R.; Rosso, S.; Dwyer, T.; Venn, A.; Kanetsky, P.A.; Groben, P.A.; Hao, H.; Orlow, I.; Reiner, A.S.; Luo, L.; Paine, S.; Ollila, D.W.; Wilcox, H.; Begg, C.B.; Berwick, M.

Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer

Teng, F.; Meng, X.; Kong, L.; Mu, D.; Zhu, H.; Liu, S.; Zhang, J.; Yu, J.

Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions

Teng, F.; Meng, X.; Wang, X.; Yuan, J.; Liu, S.; Mu, D.; Zhu, H.; Kong, L.; Yu, J.

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Hamid, O.; Schmidt, H.; Nissan, A.; Ridolfi, L.; Aamdal, S.; Hansson, J.; Guida, M.; Hyams, D.M.; Gomez, H.; Bastholt, L.; Chasalow, S.D.; Berman, D.

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P.C.; Harview, C.L.; Yearley, J.H.; Shintaku, I.P.; Taylor, E.J.; Robert, L.; Chmielowski, B.; Spasic, M.; Henry, G.; Ciobanu, V.; West, A.N.; Carmona, M.; Kivork, C.; Seja, E.; Cherry, G.; Gutierrez, A.J.; Grogan, T.R.; Mateus, C.; Tomasic, G.; Glaspy, J.A.; Emerson, R.O.; Robins, H.; Pierce, R.H.; Elashoff, D.A.; Robert, C.; Ribas, A.

Classification of advanced human cancers based on tumor immunity in the MicroEnvironment (TIME) for cancer immunotherapy

Zhang, Y.; Chen, L.

Elements of cancer immunity and the cancer-immune set point

Chen, D.S.; Mellman, I.

CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer

Naito, Y.; Saito, K.; Shiiba, K.; Ohuchi, A.; Saigenji, K.; Nagura, H.; Ohtani, H.

The clinical utility of the local inflammatory response in colorectal cancer

Richards, C.H.; Roxburgh, C.S.; Powell, A.G.; Foulis, A.K.; Horgan, P.G.; McMillan, D.C.

Cancer immune contexture and immunotherapy

Becht, E.; Giraldo, N.A.; Dieu-Nosjean, M.C.; Sautes-Fridman, C.; Fridman, W.H.

Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures

Dieu-Nosjean, M.C.; Antoine, M.; Danel, C.; Heudes, D.; Wislez, M.; Poulot, V.; Rabbe, N.; Laurans, L.; Tartour, E.; de Chaisemartin, L.; Lebecque, S.; Fridman, W.H.; Cadranel, J.

Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer

Giraldo, N.A.; Becht, E.; Pages, F.; Skliris, G.; Verkarre, V.; Vano, Y.; Mejean, A.; Saint-Aubert, N.; Lacroix, L.; Natario, I.; Lupo, A.; Alifano, M.; Damotte, D.; Cazes, A.; Triebel, F.; Freeman, G.J.; Dieu-Nosjean, M.C.; Oudard, S.; Fridman, W.H.; Sautes-Fridman, C.

Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma

Giraldo, N.A.; Becht, E.; Vano, Y.; Petitprez, F.; Lacroix, L.; Validire, P.; Sanchez-Salas, R.; Ingels, A.; Oudard, S.; Moatti, A.; Buttard, B.; Bourass, S.; Germain, C.; Cathelineau, X.; Fridman, W.H.; Sautes-Fridman, C.

"Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy

Garrido, F.; Cabrera, T.; Aptsiauri, N.

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

Johnson, D.B.; Estrada, M.V.; Salgado, R.; Sanchez, V.; Doxie, D.B.; Opalenik, S.R.; Vilgelm, A.E.; Feld, E.; Johnson, A.S.; Greenplate, A.R.; Sanders, M.E.; Lovly, C.M.; Frederick, D.T.; Kelley, M.C.; Richmond, A.; Irish, J.M.; Shyr, Y.; Sullivan, R.J.; Puzanov, I.; Sosman, J.A.; Balko, J.M.

Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer

Remon, J.; Chaput, N.; Planchard, D.

High tumoral IFNg mRNA, PD-L1 protein, and combined IFNγ mRNA/PD-L1 protein expression associates with response to durvalumab (anti-PD-L1) monotherapy in NSCLC patients [abstract]

Higgs, B.W.

PD-1 blockade in tumors with mismatch-repair deficiency

Le, D.T.; Uram, J.N.; Wang, H.; Bartlett, B.R.; Kemberling, H.; Eyring, A.D.; Skora, A.D.; Luber, B.S.; Azad, N.S.; Laheru, D.; Biedrzycki, B.; Donehower, R.C.; Zaheer, A.; Fisher, G.A.; Crocenzi, T.S.; Lee, J.J.; Duffy, S.M.; Goldberg, R.M.; de la Chapelle, A.; Koshiji, M.; Bhaijee, F.; Huebner, T.; Hruban, R.H.; Wood, L.D.; Cuka, N.; Pardoll, D.M.; Papadopoulos, N.; Kinzler, K.W.; Zhou, S.; Cornish, T.C.; Taube, J.M.; Anders, R.A.; Eshleman, J.R.; Vogelstein, B.; Diaz, L.A.

Genetic basis for clinical response to CTLA-4 blockade in melanoma

Snyder, A.; Makarov, V.; Merghoub, T.; Yuan, J.; Zaretsky, J.M.; Desrichard, A.; Walsh, L.A.; Postow, M.A.; Wong, P.; Ho, T.S.; Hollmann, T.J.; Bruggeman, C.; Kannan, K.; Li, Y.; Elipenahli, C.; Liu, C.; Harbison, C.T.; Wang, L.; Ribas, A.; Wolchok, J.D.; Chan, T.A.

Targeted next generation sequencing identifies markers of response to PD-1 blockade

Johnson, D.B.; Frampton, G.M.; Rioth, M.J.; Yusko, E.; Xu, Y.; Guo, X.; Ennis, R.C.; Fabrizio, D.; Chalmers, Z.R.; Greenbowe, J.; Ali, S.M.; Balasubramanian, S.; Sun, J.X.; He, Y.; Frederick, D.T.; Puzanov, I.; Balko, J.M.; Cates, J.M.; Ross, J.S.; Sanders, C.; Robins, H.; Shyr, Y.; Miller, V.A.; Stephens, P.J.; Sullivan, R.J.; Sosman, J.A.; Lovly, C.M.

Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1

G, F.; Johnson, D.B.; Rioth, M.J.

Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma

Smyrk, T.C.; Watson, P.; Kaul, K.; Lynch, H.T.

Somatic mutations and neoepitope homology in melanomas treated with CTLA-4 blockade

Nathanson, T.; Ahuja, A.; Rubinsteyn, A.; Aksoy, B.A.; Hellmann, M.D.; Miao, D.; Van Allen, E.; Merghoub, T.; Wolchok, J.D.; Snyder, A.; Hammerbacher, J.

Tracking the evolution of non-small-cell lung cancer

Jamal-Hanjani, M.; Wilson, G.A.; McGranahan, N.; Birkbak, N.J.; Watkins, T.B.K.; Veeriah, S.; Shafi, S.; Johnson, D.H.; Mitter, R.; Rosenthal, R.; Salm, M.; Horswell, S.; Escudero, M.; Matthews, N.; Rowan, A.; Chambers, T.; Moore, D.A.; Turajlic, S.; Xu, H.; Lee, S.M.; Forster, M.D.; Ahmad, T.; Hiley, C.T.; Abbosh, C.; Falzon, M.; Borg, E.; Marafioti, T.; Lawrence, D.; Hayward, M.; Kolvekar, S.; Panagiotopoulos, N.; Janes, S.M.; Thakrar, R.; Ahmed, A.; Blackhall, F.; Summers, Y.; Shah, R.; Joseph, L.; Quinn, A.M.; Crosbie, P.A.; Naidu, B.; Middleton, G.; Langman, G.; Trotter, S.; Nicolson, M.; Remmen, H.; Kerr, K.; Chetty, M.; Gomersall, L.; Fennell, D.A.; Nakas, A.; Rathinam, S.; Anand, G.; Khan, S.; Russell, P.; Ezhil, V.; Ismail, B.; Irvin-Sellers, M.; Prakash, V.; Lester, J.F.; Kornaszewska, M.; Attanoos, R.; Adams, H.; Davies, H.; Dentro, S.; Taniere, P.; O'Sullivan, B.; Lowe, H.L.; Hartley, J.A.; Iles, N.; Bell, H.; Ngai, Y.; Shaw, J.A.; Herrero, J.; Szallasi, Z.; Schwarz, R.F.; Stewart, A.; Quezada, S.A.; Le Quesne, J.; Van Loo, P.; Dive, C.; Hackshaw, A.; Swanton, C.

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

Akbay, E.A.; Koyama, S.; Carretero, J.; Altabef, A.; Tchaicha, J.H.; Christensen, C.L.; Mikse, O.R.; Cherniack, A.D.; Beauchamp, E.M.; Pugh, T.J.; Wilkerson, M.D.; Fecci, P.E.; Butaney, M.; Reibel, J.B.; Soucheray, M.; Cohoon, T.J.; Janne, P.A.; Meyerson, M.; Hayes, D.N.; Shapiro, G.I.; Shimamura, T.; Sholl, L.M.; Rodig, S.J.; Freeman, G.J.; Hammerman, P.S.; Dranoff, G.; Wong, K.K.

Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer

Ota, K.; Azuma, K.; Kawahara, A.; Hattori, S.; Iwama, E.; Tanizaki, J.; Harada, T.; Matsumoto, K.; Takayama, K.; Takamori, S.; Kage, M.; Hoshino, T.; Nakanishi, Y.; Okamoto, I.

Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)

Peters, S.; Gettinger, S.; Johnson, M.L.; Janne, P.A.; Garassino, M.C.; Christoph, D.; Toh, C.K.; Rizvi, N.A.; Chaft, J.E.; Carcereny Costa, E.; Patel, J.D.; Chow, L.Q.M.; Koczywas, M.; Ho, C.; Fruh, M.; van den Heuvel, M.; Rothenstein, J.; Reck, M.; Paz-Ares, L.; Shepherd, F.A.; Kurata, T.; Li, Z.; Qiu, J.; Kowanetz, M.; Mocci, S.; Shankar, G.; Sandler, A.; Felip, E.

Ann. Oncol. (Meeting Abstracts)

M, G.

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

Kadara, H.; Choi, M.; Zhang, J.; Parra, E.R.; Rodriguez-Canales, J.; Gaffney, S.G.; Zhao, Z.; Behrens, C.; Fujimoto, J.; Chow, C.; Yoo, Y.; Kalhor, N.; Moran, C.; Rimm, D.; Swisher, S.; Gibbons, D.L.; Heymach, J.; Kaftan, E.; Townsend, J.P.; Lynch, T.J.; Schlessinger, J.; Lee, J.; Lifton, R.P.; Wistuba; Herbst, R.S.

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities

Skoulidis, F.; Byers, L.A.; Diao, L.; Papadimitrakopoulou, V.A.; Tong, P.; Izzo, J.; Behrens, C.; Kadara, H.; Parra, E.R.; Canales, J.R.; Zhang, J.; Giri, U.; Gudikote, J.; Cortez, M.A.; Yang, C.; Fan, Y.; Peyton, M.; Girard, L.; Coombes, K.R.; Toniatti, C.; Heffernan, T.P.; Choi, M.; Frampton, G.M.; Miller, V.; Weinstein, J.N.; Herbst, R.S.; Wong, K.K.; Zhang, J.; Sharma, P.; Mills, G.B.; Hong, W.K.; Minna, J.D.; Allison, J.P.; Futreal, A.; Wang, J.; Wistuba; Heymach, J.V.

An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy

Tavare, R.; Escuin-Ordinas, H.; Mok, S.; McCracken, M.N.; Zettlitz, K.A.; Salazar, F.B.; Witte, O.N.; Ribas, A.; Wu, A.M.

PD-L1 detection in tumors using [(64)Cu]Atezolizumab with PET

Lesniak, W.G.; Chatterjee, S.; Gabrielson, M.; Lisok, A.; Wharram, B.; Pomper, M.G.; Nimmagadda, S.

Practical immuno-PET radiotracer design considerations for human immune checkpoint imaging

Mayer, A.T.; Natarajan, A.; Gordon, S.R.; Maute, R.L.; McCracken, M.N.; Ring, A.M.; Weissman, I.L.; Gambhir, S.S.

Rapid PD-L1 detection in tumors with PET using a highly specific peptide

Chatterjee, S.; Lesniak, W.G.; Miller, M.S.; Lisok, A.; Sikorska, E.; Wharram, B.; Kumar, D.; Gabrielson, M.; Pomper, M.G.; Gabelli, S.B.; Nimmagadda, S.

Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: does age really matter?

Ferrara, R.; Mezquita, L.; Auclin, E.; Chaput, N.; Besse, B.

Smoking, p53 mutation, and lung cancer

Gibbons, D.L.; Byers, L.A.; Kurie, J.M.

Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab

Gebhardt, C.; Sevko, A.; Jiang, H.; Lichtenberger, R.; Reith, M.; Tarnanidis, K.; Holland-Letz, T.; Umansky, L.; Beckhove, P.; Sucker, A.; Schadendorf, D.; Utikal, J.; Umansky, V.

The proportion of circulating CD45RO+CD8+ memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab

Tietze, J.K.; Angelova, D.; Heppt, M.V.; Reinholz, M.; Murphy, W.J.; Spannagl, M.; Ruzicka, T.; Berking, C.

Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab

Weide, B.; Martens, A.; Hassel, J.C.; Berking, C.; Postow, M.A.; Bisschop, K.; Simeone, E.; Mangana, J.; Schilling, B.; Di Giacomo, A.M.; Brenner, N.; Kahler, K.; Heinzerling, L.; Gutzmer, R.; Bender, A.; Gebhardt, C.; Romano, E.; Meier, F.; Martus, P.; Maio, M.; Blank, C.; Schadendorf, D.; Dummer, R.; Ascierto, P.A.; Hospers, G.; Garbe, C.; Wolchok, J.D.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Weber, J.S.; D'Angelo, S.P.; Minor, D.; Hodi, F.S.; Gutzmer, R.; Neyns, B.; Hoeller, C.; Khushalani, N.I.; Miller, W.H.; Lao, C.D.; Linette, G.P.; Thomas, L.; Lorigan, P.; Grossmann, K.F.; Hassel, J.C.; Maio, M.; Sznol, M.; Ascierto, P.A.; Mohr, P.; Chmielowski, B.; Bryce, A.; Svane, I.M.; Grob, J.J.; Krackhardt, A.M.; Horak, C.; Lambert, A.; Yang, A.S.; Larkin, J.

Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012

Y, B.; Muro, K.; Shankaran, V.; Geva, R.; Catenacci, D.V.T.; Gupta, S.

Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma

Daud, A.I.; Wolchok, J.D.; Robert, C.; Hwu, W.J.; Weber, J.S.; Ribas, A.; Hodi, F.S.; Joshua, A.M.; Kefford, R.; Hersey, P.; Joseph, R.; Gangadhar, T.C.; Dronca, R.; Patnaik, A.; Zarour, H.; Roach, C.; Toland, G.; Lunceford, J.K.; Li, X.N.; Emancipator, K.; Dolled-Filhart, M.; Kang, S.P.; Ebbinghaus, S.; Hamid, O.

Pembrolizumab versus ipilimumab in advanced melanoma

Robert, C.; Schachter, J.; Long, G.V.; Arance, A.; Grob, J.J.; Mortier, L.; Daud, A.; Carlino, M.S.; McNeil, C.; Lotem, M.; Larkin, J.; Lorigan, P.; Neyns, B.; Blank, C.U.; Hamid, O.; Mateus, C.; Shapira-Frommer, R.; Kosh, M.; Zhou, H.; Ibrahim, N.; Ebbinghaus, S.; Ribas, A.

A phase Ia study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC)

T, P.; Petrylak, D.P.; Bellmunt, J.; Braiteh, F.S.; Loriot, Y.; Zambrano, C.C.

Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab (MPDL3280 A) vs docetaxel in 2L/3L NSCLC

K, P.; Spira, A.I.; Mazières, J.; Vansteenkiste, J.F.; Rittmeyer, A.; Ballinger, M.

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with recurrent or refractory ovarian cancer: a phase Ib trial reporting safety and clinical activity

M, P.; Disis, M.L.; Pant, S.; Hamilton, E.P.; Lockhart, A.C.; Kelly, K.

	DeepDyve Freelancer	DeepDyve Pro
Price	FREE	$49/month $360/year
Save searches from Google Scholar, PubMed
Create folders to organize your research
Export folders, citations
Read DeepDyve articles	Abstract access only	Unlimited access to over 18 million full-text articles
Print		20 pages / month
PDF Discount		20% off
	Sign up for free	Start 14 day Free Trial

Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review

Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

Explore the DeepDyve Library

Search

Organize

Access

Your journals are on DeepDyve

“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”

“Whoa! It’s like Spotify but for academic articles.”

“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”

“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”

Freelancer

Pro

Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review

Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review

Abstract

Journal

Recommended Articles

References

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your personal research library

Explore the DeepDyve Library

Search

Organize

Access

Your journals are on DeepDyve

“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”

“Whoa! It’s like Spotify but for academic articles.”

“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”

“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”

Freelancer

Pro

Our policy towards the use of cookies

DeepDyve is your
personal research library